Page last updated: 2024-12-07

3,4-dihydroxybenzylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-Dihydroxybenzylamine is a naturally occurring compound found in various plants, including the bark of the *Acacia confusa* tree. It has been shown to exhibit a range of biological activities, including antioxidant, anti-inflammatory, and neuroprotective effects. Its synthesis can be achieved through various methods, including reduction of the corresponding nitro compound or through enzymatic reactions. The compound has garnered interest due to its potential therapeutic applications, particularly in the treatment of neurodegenerative diseases and oxidative stress-related conditions. Research studies have explored its effects on neuronal cells, demonstrating its ability to protect against damage induced by toxins and oxidative stress. Further investigations are underway to fully understand its mechanisms of action and explore its therapeutic potential.'

3,4-dihydroxybenzylamine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91623
CHEMBL ID2009732
CHEBI ID139382
SCHEMBL ID110644
MeSH IDM0077814

Synonyms (28)

Synonym
nsc 263475
einecs 240-382-8
NCI60_002102
1,2-benzenediol, 4-(aminomethyl)-
4-(aminomethyl)-1,2-benzenediol
3,4-dihydroxybenzylamine
brn 2082211
4-(aminomethyl)pyrocatechol hydrobromide
CHEBI:139382
74875C42-3C45-4D9C-A7EC-69ED5F375D69
FT-0691984
37491-68-2
4-(aminomethyl)benzene-1,2-diol
AKOS000134018
4-(aminomethyl)-benzene-1,2-diol
3-13-00-02183 (beilstein handbook reference)
3,4-dihydroxyl benzylamine
(3,4-dihydroxyphenyl)methanamine
3, 4 dihydroxybenzylamine
SCHEMBL110644
CHEMBL2009732 ,
4-(aminomethyl)pyrocatechol
Q26841323
noname_3263
DTXSID20902714
EN300-82137
bdbm50553158
nsc 263475 (hydrobromide)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The rationale for melanoma specific dihydroxybenzene containing antitumor agents is based in part upon the ability of the enzyme tyrosinase to oxidize these pro drugs to toxic intermediates."( Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
Fitzgerald, GB; Prezioso, JA; Wick, MM,
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" BSO demonstrated in vivo antitumor activity in B16 melanoma-bearing mice prolonging survival by 29% and in combination with 3,4-DHBA resulted in a slight (48% versus 38%) increase in life span as compared to 3,4-DHBA alone."( Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
FitzGerald, GB; Prezioso, JA; Wick, MM, 1992
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve for verapamil was bell-shaped and the activity resided in the l form."( An inhibitory effect of verapamil and diltiazem on the release of noradrenaline from ischaemic and reperfused hearts.
Nayler, WG; Sturrock, WJ, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
catecholsAny compound containing an o-diphenol component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Arginase-1Bos taurus (cattle)IC50 (µMol)164.00002.70002.70002.7000AID1695179
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
urea cycleArginase-1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1695179Inhibition of recombinant bovine liver ARGI using L-arginine as substrate incubated for 60 mins by spectroscopic analysis2020RSC medicinal chemistry, May-01, Volume: 11, Issue:5
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (58.62)18.7374
1990's13 (22.41)18.2507
2000's6 (10.34)29.6817
2010's3 (5.17)24.3611
2020's2 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.63 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]